JJJOHNSON & JOHNSON
154.6000USDD
+1.7000+1.11%
At close at May 30, 18:14 GMT
USD
No trades
Key facts today
Johnson & Johnson's Phase 3 AMPLITUDE study shows its PARP inhibitor AKEEGA effectively delays cancer progression in patients with HRR-altered metastatic castration-sensitive prostate cancer.
9.0608 USD
14.07 B USD
88.82 B USD
2.40 B
About JOHNSON & JOHNSON
Sector
Industry
CEO
Joaquin Duato
Website
Headquarters
New Brunswick
Founded
1887
FIGI
BBG00QKLW2K1
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
10%
21%
32%
43%
54%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
6.00 B
12.00 B
18.00 B
24.00 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
6.00 B
12.00 B
18.00 B
24.00 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
6.00 B
12.00 B
18.00 B
24.00 B
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0R34 is 154.6000 USD — it has increased by 1.11% in the past 24 hours. Watch JOHNSON & JOHNSON stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange JOHNSON & JOHNSON stocks are traded under the ticker 0R34.
0R34 stock has risen by 1.12% compared to the previous week, the month change is a −0.55% fall, over the last year JOHNSON & JOHNSON has showed a 6.47% increase.
0R34 reached its all-time high on Apr 26, 2022 with the price of 186.4850 USD, and its all-time low was 102.6208 USD and was reached on Nov 10, 2014. View more price dynamics on 0R34 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0R34 stock is 1.42% volatile and has beta coefficient of 0.51. Track JOHNSON & JOHNSON stock price on the chart and check out the list of the most volatile stocks — is JOHNSON & JOHNSON there?
Today JOHNSON & JOHNSON has the market capitalization of 372.14 B, it has increased by 0.42% over the last week.
Yes, you can track JOHNSON & JOHNSON financials in yearly and quarterly reports right on TradingView.
0R34 net income for the last quarter is 11.00 B USD, while the quarter before that showed 3.43 B USD of net income which accounts for 220.58% change. Track more JOHNSON & JOHNSON financial stats to get the full picture.
Yes, 0R34 dividends are paid quarterly. The last dividend per share was 1.30 USD. As of today, Dividend Yield (TTM)% is 3.25%. Tracking JOHNSON & JOHNSON dividends might help you take more informed decisions.
JOHNSON & JOHNSON dividend yield was 3.40% in 2024, and payout ratio reached 84.80%. The year before the numbers were 3.00% and 84.93% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 4, 2025, the company has 138.1 K employees. See our rating of the largest employees — is JOHNSON & JOHNSON on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JOHNSON & JOHNSON EBITDA is 28.58 B USD, and current EBITDA margin is 31.71%. See more stats in JOHNSON & JOHNSON financial statements.
Like other stocks, 0R34 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JOHNSON & JOHNSON stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JOHNSON & JOHNSON technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JOHNSON & JOHNSON stock shows the sell signal. See more of JOHNSON & JOHNSON technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.